MedTrace Logo

Study to Evaluate the Efficacy and Safety of EP-104IAR in Patients With Osteoarthritis of the Knee

NCT04120402 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 318

Last updated 2024-06-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of EP-104IAR in patients with osteoarthritis (OA) of the knee

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

EP-104IAR 25 mg

Single 5 mL intra-articular injection

DRUG

Vehicle

Single 5 mL intra-articular injection

Sponsors & Collaborators

  • NBCD A/S

    collaborator INDUSTRY

  • Eupraxia Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Amanda Malone · Eupraxia Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-10
Primary Completion
2023-05-17
Completion
2023-06-01
FDA Drug
Yes

Countries

  • Czechia
  • Denmark
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04120402 on ClinicalTrials.gov